OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company’s research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.

OKYO’s lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain. The company’s approach is designed to selectively influence disease pathways while potentially limiting unwanted effects associated with less targeted treatments. Its pipeline and platform are intended to support the discovery and development of additional medicines for serious conditions with unmet treatment needs.

OKYO Pharma is headquartered in the United Kingdom and conducts its drug-development activities with a focus on international, including U.S., clinical and regulatory opportunities. The company’s American depositary shares trade on the Nasdaq under the symbol OKYO.

Key Stats

• Today's Range: $1.31 to $1.45
• 50-Day Range: $1.28 to $1.62
• 52-Week Range: $1.26 to $3.20
• Volume: 59,877 shs
• Average Volume: 62,858 shs
• Market Capitalization: $74.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.67
• Consensus Rating: Moderate Buy

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 62% of companies evaluated by MarketBeat, and ranked 344th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OKYO Pharma has a consensus price target of $5.67, representing about 299.1% upside from its current price of $1.42.

Amount of Analyst Coverage

OKYO Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OKYO Pharma are expected to decrease in the coming year, from ($0.13) to ($0.15) per share.

Price to Book Value per Share Ratio

OKYO Pharma has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.15% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 40.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.93

News Sentiment

OKYO Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OKYO Pharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.97% of the stock of OKYO Pharma is held by institutions.

Company Calendar

• Today: 11/11/2026
• Stifel 2026 Healthcare Conference 2026: 11/12/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OKYO
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OKYO Pharma: $5.67
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +299.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.43
• Quick Ratio: 2.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 4.73

Miscellaneous

• Outstanding Shares: 52,480,000
• Free Float: 31,247,000
• Market Cap: $74.52 million
• Optionable: Not Optionable
• Beta: 0.02